Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 36 for “"anti-PD-1"”.
-
Loss of Ptdss1 in tumor cells improves anti-PD-1 therapy
… we identified PTDSS1 as a target to improve anti-PD-1 therapy. Depletion of PTDSS1 in tumor cells increased expression of IFNγ-regulated genes, including B2m, Cxcl9, Cxcl10, and Stat1. Loss of PTDSS1 in tumor cells also led to increased expression of MHC-I, which was associated with increased …
-
An Affinity Threshold for Maximum Efficacy in Anti-PD-1 Cancer Immunotherapy
Monoclonal antibodies (mAbs) targeted to the programmed cell death protein 1 (PD-1) remain the most prevalent cancer immunotherapy both as a monotherapy and in combination with additional therapies. Despite the extensive success of anti-PD-1 mAbs in the clinic, the experimental relationship between …
-
Assessing Tumor Mutation Burden and Correlation With Anti-PD-1/L1 Therapy Benefit and Prognosis
The general metadata -- e.g., title, author, abstract, subject headings, etc. -- is publicly available, but access to the submitted files is restricted to UT Southwestern campus access and/or authorized UT Southwestern users.
-
IMPAIRMENT OF TOLL-LIKE RECEPTOR 9 AGONIST ANTI-TUMOR ACTIVITY BY ANTI-PD-1 ANTIBODY: ROLE OF MACROPHAGES
… un aumento dell’espressione del recettore PD-1 sulle cellule immuni. PD-1 è espresso dalle cellule del sistema immunitario sia innato sia adattativo e, in seguito al legame con i suoi due ligandi (PD-L1 e –L2), provoca lo spegnimento dell’attività del sistema immunitario. Per sfuggire …
-
The Cx3Cl1-Cx3Cr1 Chemokine Axis Contributes to Tumor Immune Evasion and Its Blockade Enhances Responses to Anti-Pd-1 Immunotherapy
… in the underlying mechanisms of resistance to anti-PD-1 immunotherapy. We used a novel monoclonal antibody against mouse CX3CR1 that binds to CX3CR1, blocks the CX3CL1-CX3CR1 interaction and antagonizes the pro-tumorigenic outcome of this axis. This monoclonal antibody reduces migration of …
-
Tumour Associated Neutrophils as a Potential Biomarker for Anti-PD-1 Immunotherapy in Non-Small Cell Lung Carcinoma: An Automated Approach
… the molecular landscape of TANhigh tumours. Quantitative pathology features, such as granulocyte density in the tumour, were used to develop a classifier for automated TAN status prediction. Results: Manual visual scoring identified a TANhigh phenotype in approximately 18% of LUAD cases. This …
-
Investigation of The Functional Impact of Anti-Pd-1 On Tumor-Infiltrating Lymphocytes (Til) and Mapping of Tumor Genomic Features Relevant For Response to Til Therapy
<p>With the growing use of both cellular and antibody-based immunotherapies, it has become more important to uncover biomarkers to predict patient response to therapy and ideally aid in patient selection for specific therapeutics, thereby enhancing treatment outcome. At MD Anderson, we have a 43% …
-
Targeting Pd-1/Pdl-1 Signaling In The Treatment of Osteosarcoma Lung Metastasis
… such as binding of immune inhibitory receptor, PD-1 with PDL-1, which is upregulated in cancer cells, may cause disease relapse.</p> <p>The effect of PD-1 blockade on NK cells and macrophages has not been investigated till date. The aim of this study was to determine if PD-1 blockade leads to of …
-
Single-cell analyses of tumor-infiltrating immune cells
… from mice exhibiting differential responses to anti-PD-1 immunotherapy. Data analysis pipelines that allow for the mining of this data for novel cell subpopulations are also discussed. Based on our immunophenotypic analysis (multispectral image-based cytometry), we have discovered subpopulations …
-
Bhlhe40: Required For Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy
… 2012). This therapy allows for the modulation of anti-tumor responses through the use of monoclonal antibodies, such as anti-CTLA-4 or anti-PD-1 that block the receptors from binding with their ligands, thus allowing for CD4<sup>+</sup> and CD8<sup>+</sup> T cell priming and activation(Wei et al., …
-
Defining the relationship between the gut microbiome and response to combination immune checkpoint blockade across cancer types
… the proteins Programmed cell Death protein 1 (PD-1) and Cytotoxic T Lymphocyte associated protein 4 (CTLA-4) have revolutionised the treatment of many cancers, and can be used in combination for synergistic anti-tumour effect. Nevertheless, response to ICIs remain unpredictable, and we lack …
-
Improving cancer therapy strategies via cellular stress and immune modulation
… potent ErSO mediated cytotoxicity and anti-metastatic activity, significantly extending survival even in late stage, chemoresistant models. Mechanistic analyses revealed that ErSO activity is independent of estrogen receptor alpha (ERα) but critically dependent on plasma …
-
Engineering Intratumoral Cytokine Therapies for Cancer
Immunotherapies enable effective, long-lasting anti-tumor immunity for some cancer patients. Cytokines are key signaling proteins that help activate and sustain critical immune cells during this process. Unfortunately, traditional cytokine therapies suffer from low efficacy and high systemic …
-
The Efficacy of Immunotherapy in Preventing Liver Cancer and the Role of Metabolic Zonation in Its Development
… mouse model of HCC. We found that initiation of anti-PD-1 immunotherapy prior to tumorigenesis could prevent up to 46% of liver tumors. This reduction in tumor burden was accompanied by infiltration of CD4+ T helper and CD8+ cytotoxic T cells into the liver parenchyma. Importantly, anti-PD-1 …
-
Role of the Gut Microbiome in Cancer Immunotherapy Efficacy and Side Effects
… (CTLA-4) and programmed cell death protein 1 (PD-1) blockade. The research examined how gut microbiota dysbiosis influences T cell populations in various intestinal compartments during CTLA-4 blockade therapy, the connection between specific microbiota compositions and inflammatory responses, …
-
Molecular dissection of macrophage-tumour cell interactions to identify novel treatment strategies for pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive forms of adult tumours with a median survival time of twelve months. PDAC is highly resistant to conventional therapy which includes surgical resection of the tumour, radiation treatment and chemotherapy. PDAC cells are highly …
-
T-Regulatory Cells and FLT3-Ligand in the Therapy of Cockroach Antigen-induced Asthma
… CD25 and Foxp3 after exposure to inhaled antigen in the lung. However, how these cells regulate allergic airway inflammation and AHR in asthma remains ill-defined.|In this study, the effect of NTregs and iTregs, isolated from mouse lung and spleen (BALB/c), was examined by adoptive …
-
Assessment of the clinical validity of ctDNA Analysis for melanoma management
… our protocol for plasma ctDNA extraction and quantification using droplet digital PCR (Chapter 2). Using this methodology, we evaluated the ctDNA detection rate in untreated BRAF mutant melanoma patients, as a potential alternative to tumour genotyping (Chapter 3), where the potential economic …
-
Enhancing Anti-Cancer Immunotherapy by Disruption of the non-Receptor Tyrosine Kinase Fes
… of cancer, these checkpoints act as barriers to anti-cancer immunity, and therefore represent important targets for cancer immunotherapy. Here, we demonstrate a novel role of the Fes tyrosine kinase, which is abundantly expressed in macrophages, dendritic cells, NK cells and B cells, as an innate …
-
Uncovering Molecular Targets to Overcome Immunosuppression In Non-Small Cell Lung Cancer With Acquired Tki Resistance
… tyrosine kinase inhibitors (TKIs) or monoclonal antibodies targeting vascular endothelial growth factor (VEGF/R), can effectively inhibit upregulated signaling pathways driving tumorigenesis in NSCLC and many other cancers. Unfortunately, however, resistance to such targeted therapies inevitably …
Page 1 of 2